Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariona Pascal

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Nature Communications|February 5, 2026
An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergensMark Møiniche, Kristoffer H Johansen, Jorge Parrón-Ballesteros, et al.
Transplantation Direct|October 17, 2022
Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort StudyDavid Cucchiari, Natalia Egri, Diana Rodriguez-Espinosa, et al.
Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.
Allergy|February 13, 2022
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position PaperChristoph Bergmann, Aurélie Poli, Ioana Agache, et al.
Allergy|January 24, 2024
AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paperMichelle C Turner, Urszula Radzikowska, Denisa E Ferastraoaru, et al.
American Journal of Hematology|March 7, 2022
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary diseaseValentín Ortiz-Maldonado, Anna Alonso-Saladrigues, Marta Español-Rego, et al.
Allergy|August 29, 2025
Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping ReviewRodolfo Bianchini, Andrea Escolar-Pena, Vanda Pick, et al.
British Journal of Haematology|October 31, 2023
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
The Lancet. Oncology|July 6, 2023
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyAina Oliver-Caldés, Verónica González-Calle, Valentín Cabañas, et al.
British Journal of Haematology|June 19, 2024
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cellsIñaki Ortiz de Landazuri, Aina Oliver-Caldés, Marta Español-Rego, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Nature Communications|February 5, 2026
An mRNA-delivered consensus allergen induces a neutralizing IgG response against food and pollen allergensMark Møiniche, Kristoffer H Johansen, Jorge Parrón-Ballesteros, et al.
Transplantation Direct|October 17, 2022
Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort StudyDavid Cucchiari, Natalia Egri, Diana Rodriguez-Espinosa, et al.
Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.
Allergy|February 13, 2022
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position PaperChristoph Bergmann, Aurélie Poli, Ioana Agache, et al.
Allergy|January 24, 2024
AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paperMichelle C Turner, Urszula Radzikowska, Denisa E Ferastraoaru, et al.
American Journal of Hematology|March 7, 2022
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary diseaseValentín Ortiz-Maldonado, Anna Alonso-Saladrigues, Marta Español-Rego, et al.
Allergy|August 29, 2025
Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping ReviewRodolfo Bianchini, Andrea Escolar-Pena, Vanda Pick, et al.
British Journal of Haematology|October 31, 2023
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
The Lancet. Oncology|July 6, 2023
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyAina Oliver-Caldés, Verónica González-Calle, Valentín Cabañas, et al.
British Journal of Haematology|June 19, 2024
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cellsIñaki Ortiz de Landazuri, Aina Oliver-Caldés, Marta Español-Rego, et al.
Pageof 8